Henlius Reports First Fully Profitable Year After Past Losses

The Result Continues The Trend Of Increased Sales Growth

After reporting losses for the past two years, the Chinese pharma announced the first full year of profitability on the back of continued sales of its commercialized assets.

China flag, vial dose, needle syringe — • Source: Shutterstock

Shanghai Henlius Biotech has achieved its first full year of profitability in 2023 on the back of increased sales and growing sales volume, marking a change from the last two years’ of reported losses.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

02 May 2025

• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

What’s Next? Five Things To Look Out For In May

01 May 2025

• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

28 Apr 2025

• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

Samsung Bioepis Grows After US Launches

25 Apr 2025

• By Dave Wallace

Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.